Belville W D, Cox H D, Mahan D E, Olmert J P, Mittemeyer B T, Bruce A W
Cancer. 1978 Jun;41(6):2286-91. doi: 10.1002/1097-0142(197806)41:6<2286::aid-cncr2820410629>3.0.co;2-2.
A double-antibody radioimmunoassay was developed and utilized to measure prostatic acid phosphatase in bone marrow aspirates. One hundred-eighteen patients with carcinoma of the prostate in various clinical stages, and fifty with benign prostatic hyperplasia were studied. In patients with carcinoma, levels of prostatic acid phosphatase in bone marrow aspirates were found to correlate well with increasing clinical stage of the disease. Determination of bone marrow prostatic acid phosphatase by radioimmunoassay may be a valuable adjunct to clinicopathologic staging of prostatic carcinoma.
开发并运用了一种双抗体放射免疫分析法来测定骨髓穿刺液中的前列腺酸性磷酸酶。对118例处于不同临床阶段的前列腺癌患者和50例良性前列腺增生患者进行了研究。在前列腺癌患者中，发现骨髓穿刺液中前列腺酸性磷酸酶的水平与疾病临床阶段的进展密切相关。通过放射免疫分析法测定骨髓前列腺酸性磷酸酶可能是前列腺癌临床病理分期的一项有价值的辅助手段。
